QCI Interpret for Oncology

Is it oncogenic? Comparing guidelines and QCI Interpret CDS for cancer...

Fri, 27 Feb 2026 19:01:46 GMT

Accurate clinical interpretation of somatic cancer variants is critical for diagnosis and guidance of precision oncology treatment. Without shared standards, laboratories and clinical decision-support (CDS) systems have implemented independent approaches, leading to significant variability and highlighting a need for standardization.

Through a collaborative effort, ClinGen, the Cancer Genomics Consortium (CGC) and the Variant Interpretation for Cancer Consortium (VICC) have developed a framework for standardized classification. In this webinar, we will evaluate these standards and compare their classifications with results from the QIAGEN Clinical Insight (QCI) Interpret CDS system.

You will learn:

Understand ClinGen/CGC/VICC standards for variant classification
Learn how these expert-developed guidelines define and standardize somatic cancer variant classification.
Compare software classifications with guideline-based human assessments
See how classifications from the ClinGen/CGC/VICC standards compare with those generated by QCI Interpret.
Best practices to use guidelines and tools together
Discover how to combine expert guidelines with clinical decision support tools for more reliable variant interpretation.

S2I oncology

Thu, 10 Jul 2025 21:48:44 GMT

S2I oncology

Streamline clinical reporting for high-throughput oncology NGS testing with...

Thu, 13 Mar 2025 09:57:48 GMT

With the rising demand for personalized cancer treatments, clinical diagnostic labs are under increasing pressure to expand their capabilities, boost test throughput, shorten turnaround times, and produce detailed, oncologist-ready reports that quickly align patients with the most suitable therapies and clinical trials.

In this webinar, learn how QCI Interpret, clinical decision support software for variant interpretation and reporting, can help your lab accelerate clinical reporting workflows for high-throughput precision oncology NGS testing. The webinar will showcase QCI Interpret’s ability to streamline variant interpretation by dynamically computing pathogenicity and actionability for each variant based on ACMG and AMP/ASCO/CAP guidelines, covering more than 30,000 cancer types and subtypes with full transparency and supporting references. You’ll also learn how to utilize over 600,000 pre-formulated, oncologist-reviewed variant interpretation summaries to create customizable, up-to-date, oncologist-ready reports with detailed gene, variant, diagnostic, prognostic, and therapeutic information. Additionally, attendees will get an exclusive preview of the software’s new features designed to further optimize the somatic interpretation workflow.

Viewers will:

 Discover how QCI Interpret’s newly added Reflex function allows you to effortlessly resubmit a pre-analyzed test for full curation, enabling you to obtain a comprehensive expert review and content for uncurated variants with ease.
Get a preview of the latest oncology workflow enhancements, including retaining user-specific treatment decisions in a variant-diagnosis specific manner, automatic reapplication of the somatic reporting policy when pathogenicity classification or reportability status changes, and the addition of ClinGen/VICC scores in the variant details page.
Explore how QCI Interpret, a panel- and sequencer-agnostic software and its underlying knowledge base that integrates QIAGEN's expert curation with AI-powered machine curation to enable accurate, consistent identification of relevant literature, treatments, and clinical trials, provides an optimal solution that addresses key bottlenecks in your clinical oncology workflow.

How to accelerate your clinical reporting workflow for high-throughput...

Sat, 17 Aug 2024 22:22:39 GMT

As the demand for personalized cancer treatment grows, clinical diagnostic labs are facing unprecedented pressure to scale-up, increase test throughput, reduce turnaround times, and deliver comprehensive, oncologist-ready reports that match patients to the most appropriate therapies and clinical trials, in a time-efficient manner.

In this webinar, learn how QIAGEN Clinical Insight (QCI) Interpret for Oncology, the world’s leading variant interpretation and reporting software, can help your lab accelerate your clinical reporting workflow for high-throughput precision oncology NGS testing. The webinar will demonstrate the capabilities and features of QCI Interpret for Oncology through an example workflow for comprehensive genomic profiling. Key highlights include the software’s capability to expedite variant interpretation, dynamically compute pathogenicity and actionability based on the ACMG and AMP/ASCO/CAP guidelines for every variant in over 30,000 cancer types and subtypes with full transparency. Additionally learn how to leverage over 500,000 pre-formulated, oncologist-reviewed variant interpretation summaries to build customizable, oncologist-ready reports with up-to-date gene, variant, diagnostic, prognostic and therapeutic information.

Topics covered in this webinar:
- QCI Interpret for Oncology’s new performance and scalability enhancements, including bulk variant assessment, flagging of co-occurring variants, and a somatic reporting policy that allows users to set pathogenicity in a phenotype-agnostic manner.
- Learn how the panel- and sequencer-agnostic software can facilitate true scalability by rendering efficient test and process management capabilities, quick identification and comparison of tests from a patient for follow-up.
- How the software’s underlying knowledge base combines the unmatched accuracy and consistency of QIAGEN’s proprietary expert (MD/PhD) curation with the superior efficiency of machine curation (AI-powered) to identify all the literature, treatments, and clinical trials relevant to a patient’s tumor type with just one-click.

The Implementation Journey of Comprehensive Cancer Genome Profiling and...

Fri, 16 Aug 2024 13:29:53 GMT

This session traces the evolution of comprehensive cancer genome profiling (CGP) and liquid biopsy techniques in South East Asia, discussing the initial hurdles and ultimate triumphs. It details how interventions like international collaborations, technological enhancements, and policy support have enabled these advanced diagnostic tools' successful adoption. Highlighting the critical role of liquid biopsy in early cancer detection and monitoring treatment efficacy, the study underscores the importance of continued genomics research and investment for improved cancer care globally. It illustrates that, despite significant challenges, integrating advanced genomic profiling into oncology practice is attainable and transformative.

Benefits of integrating targeted next-generation sequencing (NGS) panels into...

Thu, 18 Jul 2024 16:20:54 GMT

Variant detection of multiple genes from a single tumor sample requires high-throughput molecular testing. To meet this demand, targeted next-generation sequencing (NGS) panels are useful in clinical settings for accurate tumor profiling and the identification of essential molecular aberrations for personalized therapies. By focusing only on a subset of genes, targeted NGS is not only a cost-effective solution, but can rapidly deliver insights into a tumor molecular profile.

To address this challenge, a clinical research team led by Dr. Michela Bulfoni at the Istituto di Anatomia Patologica designed custom NGS panels, named “Glioma” and “Routine Diagnostics”, targeting single nucleotide variations, insertions/deletions, fusions, and copy number variations of tumor-associated essential genes.

In this webinar, attendees will:
- Understand the clinical utility of custom-designed NGS panels for accurate tumour diagnosis
- Learn about the design and application of these NGS panels
- Gain insights into the cost-effectiveness and high sensitivity of NGS panels in improving sample throughput

Category: QCI Interpret for Oncology, Sample to Insight

Sample to Insight Oncology

Thu, 18 Jul 2024 00:07:21 GMT

Sample to insight solution for any oncology applocation

Expert panel: Mitigating variability in somatic variant interpretation

Thu, 06 Jun 2024 19:25:52 GMT

Next-generation sequencing (NGS) oncology panels are becoming integral in hospital and academic settings to guide patient treatment and enrollment in clinical trials. But as NGS is increasingly used in precision oncology and an unprecedented amount of genomic information is uncovered, there is an industry-wide issue of standardization: a high degree of variability in variant interpretation currently exists across laboratories.

Inconsistencies in variant interpretation among laboratories can create confusion for clinicians and their patients, leaving them unable to confidently use genetic information to manage healthcare decisions. In this previously aired live panel discussion, experts in NGS testing and clinical informatics explore the issues surrounding the standardization of variant interpretation and consider how interpretation guidelines and clinical decision support (CDS) software can help to mitigate variability between laboratories.

Topics of discussion include:

Findings of a peer-reviewed study comparing the accuracy and consistency of variant assessments from commercial CDS software to the internal variant interpretation methods of eight laboratories.
Causes of inter-laboratory inconsistency in variant interpretation and how to mitigate variability.
The benefits of having an up-to-date, high-quality knowledge base to produce consistent, evidence-based clinical classifications.

Clinician’s Roundtable: Interpreting genomic test results for precision oncology

Tue, 21 May 2024 15:22:54 GMT

You’re invited to attend the 2024 Clinician’s Roundtable, a virtual event where medical directors and oncologists will discuss how to better interpret genomic test results to tailor treatment strategies for cancer patients. As the role of the Molecular Tumor Board (MTB) becomes increasingly important in the implementation of evidence-based precision cancer medicine programs, molecular pathology labs must overcome challenges in genomic test interpretation to ensure maximum clinical utility of molecular profiling results.

At this event, hear from clinicians at leading universities and organizations as they present real-world case studies of how molecular pathology labs can improve test turnaround, standardize test interpretation, and deliver comprehensive genomic reports with personalized diagnostic, prognostic, and therapeutic information for each patient.

The free-to-attend virtual event will consist of four educational parts:

1. Case Presentations: Clinicians from Dana Farber Cancer Institute and the National Cancer Institute will present cases of how their labs have overcome challenges in genomic test interpretation.

2. Live Q&A Session: Attendees will have the opportunity to ask the clinicians questions about their experiences implementing precision oncology programs at their institutions.

3. Solution Showcase: In a brief presentation, experts from QIAGEN Digital Insights will showcase our leading Sample to Insight solutions for molecular tumor profiling.

4. Future Forecast: The event will conclude with a short presentation about how molecular tumor profiling will change in the next five years and how labs can leverage new technologies to improve patient care.

Agilent Alissa to QCI Interpret: How can your lab reduce the stress and...

Tue, 26 Mar 2024 17:54:22 GMT

In 2023, Agilent announced the discontinuation of their Alissa Interpret clinical informatics platform by the end of 2024. As a result, many of their current customers need to transition to a new variant interpretation and reporting software within a tight timeframe. However, when evaluating new interpretation solutions, clinical labs must consider a variety of factors, including:

Content quality for clinical reporting
Flexibility to adapt current workflows to a new platform
Retaining historical content and comments
Ease of personnel training

In this webinar, learn about QCI Interpret, a panel- and sequencer-agnostic clinical informatics platform for NGS variant interpretation and reporting of germline and somatic tests. Our experts will address the concerns of current Alissa users and discuss what sets QCI Interpret apart from other interpretation solutions. In addition, we will show you how seamless it is to transition to QCI Interpret, as well as provide a live demonstration of the industry-leading and reliable software that has been used to analyze and interpret more than 3.5 million patient test cases worldwide.

How to scale-up comprehensive genomic profiling and deliver confident variant...

Fri, 10 Nov 2023 13:58:00 GMT

As gene panels increase in size, comprehensive genomic profiling and variant interpretation becomes more complex and time-consuming, which places tremendous burden on labs needing to scale and grow case volume. QIAGEN Clinical Insight (QCI) Interpret for Oncology is a clinical decision support platform powered by augmented molecular intelligence that enables rapid, evidence-powered comprehensive genomic profiling at scale. QCI Interpret for Oncology is supported by the world’s most comprehensive, manually curated knowledge base and dynamically computes variant classifications according to AMP/ASCO/CAP and ACMG/AMP guidelines with transparency. Users also get access to over 500,000 pre-formulated, oncologist-reviewed variant interpretation summaries and can build customizable, oncologist-ready reports with the latest diagnostic and prognostic information, as well as biomarker-directed therapeutic information and clinical trial recommendations. With its latest release, QCI Interpret for Oncology adds several new capabilities that further enhances the platform’s scalability and flexibility, and enables users to significantly reduce variant research and review time.

In this webinar, attendees will learn how QCI Interpret for Oncology enables you to:

Navigate from VCF to final report with speed, precision, and confidence;
Easily issue report addendums without the need for re-running a VCF;
Streamline structural variant filtering based on user set thresholds and hence reduce the time and effort needed to eliminate noise and identify truly relevant variants for reporting;
Utilize built-in AI capabilities to identify all the literature, case reports, drug therapies, and clinical studies relevant to a patient’s tumor type with just one-click.

Real-World Applications of Clinical Metagenomic Sequencing in Cancer and...

Wed, 25 Oct 2023 13:25:00 GMT

Clinical metagenomic next-generation sequencing (mNGS), the comprehensive analysis of microbial and host DNA and RNA in samples from patients, is rapidly moving from research to clinical laboratories. This emerging approach is changing the diagnosis and treatment of diseases, with applications in a range of areas, including oncology, human host gene expression (transcriptomics), and antimicrobial infections and resistance.

In this webinar, Elif Dagdan, the director of the Center for Medical Genetics at Augusta Hospital Bochum in Bochum, Germany, will discuss real-world applications of using clinical mNGS to improve diagnostics of cancer and infectious diseases. The talk will also feature challenges and opportunities of using mNGS in disease diagnostics and how Dagdan’s lab uses clinical variant interpretation and reporting software from Qiagen to detect and characterize pathogenic somatic variants.

Dagdan will discuss:

How mNGS can be used to assess homologous recombination deficiency (HRD) status in patients with ovarian cancer.
How mNGS can be used to assess cell-free microbial DNA via liquid biopsy to aid in early-stage lung cancer diagnosis.
How mNGS can improve the accuracy and speed of infectious disease diagnostics, with a use-case on cardiovascular infections in intensive care units.

Scale your comprehensive genomic profiling workflow with superior automated...

Wed, 28 Jun 2023 16:02:07 GMT

Automating and scaling a comprehensive genomic profiling workflow can be a tedious and challenging process that requires lots of time and resources. However, an intelligent clinical decision support platform and on-demand expert support services can make all the difference.

In this webinar, learn about QIAGEN Clinical Insight (QCI) Interpret for Oncology, a clinical decision support platform that has been trusted to analyze and interpret more than 3 million patient molecular profiles worldwide. Unlike other commercial solutions, QCI Interpret for Oncology is powered by augmented molecular intelligence and offers in-software access to a team of variant scientists to assist you with rare or novel variant research, curation, and interpretation. The platform connects to the QIAGEN Knowledge Base—the highest quality genomic knowledge base in the industry—and dynamically computes variant classifications according to AMP/ASCO/CAP and ACMG/AMP guidelines. To help you further scale and reduce hands-on time, QCI Interpret for Oncology provides over 410,000 variant interpretation summaries that have all been reviewed by oncologists. This enables you to quickly build custom reports for your oncologists and their patients with the latest diagnostic and prognostic information, as well as biomarker-directed therapy and clinical trial recommendations.

By attending viewing this webinar, you will:

Receive a step-by-step guide of how to go from VCF to final report using QCI Interpret for Oncology
Learn about the platform’s automated variant classification process
Learn how QIAGEN uses augmented molecular intelligence to enhance our expert curation process
See first-hand how to build a custom report with an opportunity to submit your own VCF file for a sample report

Comprehensive Molecular Tumor Analysis with Alacris Theranostics

Thu, 09 Mar 2023 16:16:33 GMT

Precision oncology approaches have made great strides harnessing individual tumor mutation profiles to guide targeted therapy choices. However, deeper molecular insights are needed to improve personalized treatment decisions. Integrating gene expression analysis in personalized oncology provides an additional level of insight. These analyses include evaluating expressed mutations and drug targets, novel gene fusions, clinically relevant signatures, and the tumor immune microenvironment (TME).

Alacris Theranostics developed the Comprehensive Molecular Tumor Analysis (CMTA), a NGS-based tumor diagnostic test. The test integrates whole exome and transcriptomic sequencing (WES and RNAseq). The test deploys as an end-to-end accredited diagnostic platform from tumor sample uptake (FFPE or frozen) to personalized clinical interpretation reports. CMTA is a tumor-agnostic test that displays a unique molecular view of each sample. CMTA is a useful approach for refractory cancers with complex patterns or tumors of unknown origin.

In this webinar, viewers will:

Learn about the strategy implemented in Alacris’ bioinformatics pipeline to identify cancer-relevant somatic events
Learn how Alacris uses QCI Interpret for Oncology to annotate variants and identify potential therapies
Be eligible for a complimentary QCI Interpret demo and sample report

Mitigating Variability in Somatic Variant Interpretation: An Expert Panel

Mon, 16 Jan 2023 18:30:38 GMT

Inconsistencies in variant interpretation among laboratories can create confusion for clinicians and their patients, leaving them unable to confidently use genetic information to manage healthcare decisions. In this live panel discussion, experts in NGS testing and clinical informatics explore the issues surrounding the standardization of variant interpretation and consider how interpretation guidelines and clinical decision support (CDS) software can help to mitigate variability between laboratories.

Topics of discussion include:

Findings of a peer-reviewed study comparing the accuracy and consistency of variant assessments from commercial CDS software to the internal variant interpretation methods of eight laboratories.
Causes of inter-laboratory inconsistency in variant interpretation and how to mitigate variability.
The benefits of having an up-to-date, high-quality knowledge base to produce consistent, evidence-based clinical classifications.

50 to 500 genes: Scale-up to comprehensive genomic profiling

Wed, 13 Jul 2022 08:28:03 GMT

In this webinar, we present a workflow-agnostic, informatics software solution that enables clinical diagnostic labs to scale to CGP while reducing cost, time, and labor. Already used and trusted to interpret over 3 million patient cases worldwide, this software solution leverages the world’s largest and fastest-growing knowledge base to simplify and accelerate variant interpretation and build custom, patient-specific reports with the latest diagnostic and prognostic information, as well as biomarker-directed therapies and clinical trials.

In this webinar, you will:

Learn how to overcome unique challenges of CGP, including identifying incidental germline findings and interpreting co-occurring variants.
See why 90,000 users trust QIAGEN Digital Insights for knowledge curation—how we have built the most trusted, fastest growing knowledge base and why our curation process is unrivalled in the industry.
Receive step-by-step guide of how to perform CGP and go from VCF to final report with greater speed, precision, and confidence (all registrants can receive custom report if VCF files are provided).
Qualify for a complimentary demonstration and trial of this industry-leading software to see how your lab can scale to CGP while reducing costs, time, and labor.